Actelion Is Building 50-Rep U.S. Sales Force For Tezosentan, TNKase
Executive Summary
The Swiss pharmaceutical company Actelion plans to have a 50-rep sales force in the U.S. by the middle of 2001 to support the launch of Genentech's TNKase and its own tezosentan.
You may also be interested in...
Roche Spin-Off Basilea Will Take Over Dermatologic, Anti-Infective R&D
Roche is outsourcing its dermatological and infectious diseases research programs through the R&D spin-off Basilea Pharmaceutica.
Roche Spin-Off Basilea Will Take Over Dermatologic, Anti-Infective R&D
Roche is outsourcing its dermatological and infectious diseases research programs through the R&D spin-off Basilea Pharmaceutica.
Genentech TNKase/ReoPro Study Looking At New Use For Activase Successor
FDA wants Genentech to move promptly to update labeling for its Activase-successor product TNKase once data from ongoing combination therapy trials are available.